Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 24, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 25, 2026
CEOOther
Context
Classification
other
Code D — not an open-market trade
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-103540
Filed / recorded
Sep 25, 2026, 8:31 PM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ORAMED PHARMACEUTICALS INC.
Issuer CIK
1176309
Ticker
ORMP
Reporting person
Nadav Kidron
Relationship
Director, Officer
Officer title
President and CEO
Security
Stock option (right to buy)
Table
Derivative (Table II)
Transaction date
Sep 24, 2026
Transaction code
D
Shares / units
150,000
Acquired / disposed
Disposed (D)
Shares owned after
0
Ownership form
Direct
Amendment
No
Footnotes from the filing
On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 349,497 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
The canceled option provided for vesting in 4 equal installments as follows: 37,500 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.